In adults with t(8;21)AML, posttransplant RUNX1/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification

Blood

Volumn 124, Issue 12, 2014, Pages 1880-1886

  Wang, Yu ^a   Wu, De Pei ^b   Liu, Qi Fa ^c   Qin, Ya Zhen ^a   Wang, Jing Bo ^d   Xu, Lan Ping ^a   Liu, Yan Rong ^a   Zhu, Hong Hu ^a   Chen, Jia ^b   Dai, Min ^c   Huang, Xiao Jun ^a,e  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^c FIRST MILITARY MEDICAL UNIVERSITY   (China)

^d Aero Space Center Hospital   (China)

^e Tsinghua University   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RUNX1; TRANSCRIPTION FACTOR RUNX1T1; UNCLASSIFIED DRUG; MESSENGER RNA; ONCOPROTEIN; RNA; RUNX1 PROTEIN, HUMAN; RUNX1T1 PROTEIN, HUMAN; STEM CELL FACTOR RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CHIMERA; DISEASE FREE SURVIVAL; DNA FINGERPRINTING; DONOR LYMPHOCYTE INFUSION; FEMALE; FOLLOW UP; GENE MUTATION; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INDUCTION CHEMOTHERAPY; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; ONCOGENE C KIT; PATIENT MONITORING; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE RISK; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SHORT TANDEM REPEAT; SINGLE NUCLEOTIDE POLYMORPHISM; ADOLESCENT; CHROMOSOME 21; CHROMOSOME 8; GENE TRANSLOCATION; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MUTATION; RECURRENT DISEASE; RISK FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; CHROMOSOMES, HUMAN, PAIR 21; CHROMOSOMES, HUMAN, PAIR 8; CORE BINDING FACTOR ALPHA 2 SUBUNIT; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; NEOPLASM, RESIDUAL; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-KIT; RECURRENCE; RISK FACTORS; RNA, MESSENGER; RNA, NEOPLASM; TRANSCRIPTION FACTORS; TRANSLOCATION, GENETIC; TRANSPLANTATION CHIMERA; YOUNG ADULT;

EID: 84907194943     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-03-563403     Document Type: Article

References (24)

1. Nguyen S. Leblanc T, Fenaux P, et al. A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup. Blood 2002;99(10): 3517-3523.
2. Schlenk RF, Benner A, Krauter J, et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol. 2004; 22(18):3741-3750.
3. Marcucci G, Mrózek K, Ruppert AS, et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol. 2005; 23(24):5705-5717.
4. Appelbaum FR, Kopecky KJ, Tallman MS, et al. The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. Br J Haematol 2006;135(2): 165-173.
5. Kuwatsuka Y, Miyamura K, Suzuki R, et al. Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: t(8;21) and inv(16) represent different clinical outcomes. Blood 2009;113(9):2096-2103.
6. Perea G, Lasa A, Aventín A, et al; Grupo Cooperativo para el Estudio y Tratamiento de las Leucemias Agudas y Miel. Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]. Leukemia. 2006;20(1):87-94.
7. Weisser M, Haferlach C, Hiddemann W, Schnittger S. The quality of molecular response to chemotherapy is predictive for the outcome of AML1-ETO-positive AML and is independent of pretreatment risk factors. Leukemia. 2007;21(6): 1177-1182.
8. Lane S, Saal R, Mollee P, et al. A 1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapse. Leuk Lymphoma 2008;49(3):517-523.
9. Liu Yin JA, O'Brien MA, Hills RK, Daly SB, Wheatley K, Burnett AK. Minimal residual disease monitoring by RT-qPCR in core-binding factor AML allows risk-stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. Blood 2012;120(14):2826-2835.
10. Jourdan E, Boissel N, Chevret S, et al; French AML Intergroup. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood 2013;121(12):2213-2223.
11. Paschka P, Marcucci G, Ruppert AS, et al; Cancer and Leukemia Group B. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol. 2006;24(24):3904-3911.
12. Zhu HH, Zhang XH, Qin YZ, et al. MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial. Blood 2013;121(20):4056-4062.
13. Candoni A, Tiribelli M, Toffoletti E, et al. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia. Eur J Haematol 2009;82(1):61-68.
14. Zhao XS, Yan CH, Liu DH, et al. Combined use of WT1 and flow cytometry monitoring can promote sensitivity of predicting relapse after allogeneic HSCT without affecting specificity. Ann Hematol. 2013;92(8):1111-1119.
15. Pozzi S, Geroldi S, Tedone E, et al. Leukaemia relapse after allogeneic transplants for acute myeloid leukaemia: predictive role of WT1 expression. Br J Haematol 2013;160(4):503-509.
16. Yan CH, Liu DH, Liu KY, et al. Risk stratificationdirected donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood 2012;119(14):3256-3262.
17. Krauter J, Gorlich K, Ottmann O, et al. Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias. J Clin Oncol. 2003;21(23):4413-4422.
18. Leroy H, de Botton S, Grardel-Duflos N, et al. Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21). Leukemia. 2005; 19(3):367-372.
19. Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-a Europe Against Cancer program. Leukemia. 2003;17(12):2318-2357.
20. Alizadeh M, Bernard M, Danic B, et al. Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction. Blood 2002;99(12):4618-4625.
21. Maas F, Schaap N, Kolen S, et al. Quantification of donor and recipient hemopoietic cells by real-time PCR of single nucleotide polymorphisms [published correction appears in Leukemia. 2004;18(3): 663]. Leukemia. 2003;17(3):621-629.
22. Maas F, Schaap N, Kolen S, et al. Quantification of donor and recipient hemopoietic cells by real-time PCR of single nucleotide polymorphisms [published correction appears in Leukemia. 2004;18(3): 663]. Leukemia. 2003;17(3):630-633.
23. Qin XY, Li GX, Qin YZ, et al. Quantitative chimerism kinetics in relapsed leukemia patients after allogeneic hematopoietic stem cell transplantation. Chin Med J (Engl). 2012;125(11): 1952-1959.
24. Qin XY, Li GX, Qin YZ, et al. Quantitative assessment of hematopoietic chimerism by quantitative real-time polymerase chain reaction of sequence polymorphism systems after hematopoietic stem cell transplantation. Chin Med J (Engl). 2011;124(15):2301-2308.